CoChat
Sign Up
Cited by 1

The DOI matches its Crossref record.

Expression levels of miR‑205 and miR‑506 in colon cancer tissuesand their relationships with clinicopathological features

Jing, Nan, Yin, Lili, Sun, Junxi, Cao, Zhongzheng, Mao, Weizheng·2018·Oncology Letters
DOI 10.3892/ol.2018.9146PMC PMC6126165
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ol.2018.9146

Cites

Statistics

Figures

Figure 1. Expression levels of miR-205 and miR-506 in colon cancer tissues and para-carcinoma tissues. In the figure, the comparisons of the expression levels of miR-205 and miR-506 in colon cancer tissues and para-carcinoma tissues are shown: 1.105±0.094 vs. 1.806±0.424; 1.484±0.273 vs. 3.147±0.441; in statistical analyses, *P<0.05.
Figure 1. Expression levels of miR-205 and miR-506 in colon cancer tissues and para-carcinoma tissues. In the figure, the comparisons of the expression levels of miR-205 and miR-506 in colon cancer tissues and para-carcinoma tissues are shown: 1.105±0.094 vs. 1.806±0.424; 1.484±0.273 vs. 3.147±0.441; in statistical analyses, *P<0.05.CC BY-NC-ND · PubMed Central
Figure 2. Differential expression levels of miR-205 and miR-506 in plasma of colon cancer patients and healthy control group. Comparisons of miR-205 and miR-506 in plasma in patient group and control group are shown: 1.341±0.127 vs. 2.579±1.655; 1.574±0.304 vs. 4.541±1.419; in statistical analyses, *P<0.05.
Figure 2. Differential expression levels of miR-205 and miR-506 in plasma of colon cancer patients and healthy control group. Comparisons of miR-205 and miR-506 in plasma in patient group and control group are shown: 1.341±0.127 vs. 2.579±1.655; 1.574±0.304 vs. 4.541±1.419; in statistical analyses, *P<0.05.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. Siegel, 2015, Cancer statistics, 2015, CA Cancer J Clin, 5, 7
  2. Huang, 2010, Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer, Int J Cancer, 127, 118, 10.1002/ijc.25007 · DOI
  3. Terzić, 2010, Inflammation and colon cancer, Gastroenterology, 138, e5
  4. Buunen, 2009, Colon Cancer Laparoscopic or Open Resection Study Group: Survival after laparoscopic surgery versus open surgery for colon cancer: Long-term outcome of a randomised clinical trial, Lancet Oncol, 10, 44, 10.1016/S1470-2045(08)70310-3 · DOI
  5. Schetter, 2008, MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma, JAMA, 299, 425, 10.1001/jama.299.4.425 · DOI
  6. Shen, 2012, MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin, Med Oncol, 29, 2473, 10.1007/s12032-011-0156-x · DOI
  7. Xiao, 2017, MicroRNA-34c-3p promotes cell proliferation and invasion in hepatocellular carcinoma by regulation of NCKAP1 expression, J Cancer Res Clin Oncol, 143, 263, 10.1007/s00432-016-2280-7 · DOI
  8. Fattore, 2017, MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma, Cytokine Growth Factor Rev, 36, 39, 10.1016/j.cytogfr.2017.05.003 · DOI
  9. Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method, Methods, 25, 402, 10.1006/meth.2001.1262 · DOI · Paper page
  10. Douaiher, 2017, Colorectal cancer-global burden, trends, and geographical variations, J Surg Oncol, 115, 619, 10.1002/jso.24578 · DOI
  11. Munteanu, 2009, Multi-target QPDR classification model for human breast and colon cancer-related proteins using star graph topological indices, J Theor Biol, 257, 303, 10.1016/j.jtbi.2008.11.017 · DOI
  12. Ha, 2014, Regulation of microRNA biogenesis, Nat Rev Mol Cell Biol, 15, 509, 10.1038/nrm3838 · DOI · Paper page
  13. Inui, 2010, MicroRNA control of signal transduction, Nat Rev Mol Cell Biol, 11, 252, 10.1038/nrm2868 · DOI
  14. Cheng, 2011, Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis, PLoS One, 6, e17745, 10.1371/journal.pone.0017745 · DOI
  15. Yu, 2015, miR-21 and miR-145 cooperation in regulation of colon cancer stem cells, Mol Cancer, 14, 98, 10.1186/s12943-015-0372-7 · DOI
  16. Cekaite, 2012, MiR-9, −31, and −182 deregulation promote proliferation and tumor cell survival in colon cancer, Neoplasia, 14, 868, 10.1593/neo.121094 · DOI
  17. Karaayvaz, 2011, Prognostic significance of miR-215 in colon cancer, Clin Colorectal Cancer, 10, 340, 10.1016/j.clcc.2011.06.002 · DOI · Paper page
  18. de Carvalho, 2015, Accuracy of microRNAs as markers for the detection of neck lymph node metastases in patients with head and neck squamous cell carcinoma, BMC Med, 13, 108, 10.1186/s12916-015-0350-3 · DOI
  19. Ruiz, 2015, MicroRNAs and oncolytic viruses, Curr Opin Virol, 13, 40, 10.1016/j.coviro.2015.03.007 · DOI
  20. Zhang, 2015, MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2, Oncotarget, 6, 32586, 10.18632/oncotarget.5309 · DOI
  21. Tölle, 2013, Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer, Oncol Rep, 30, 1949, 10.3892/or.2013.2621 · DOI
  22. Agaoglu, 2011, Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer, Tumour Biol, 32, 583, 10.1007/s13277-011-0154-9 · DOI
  23. Schwarzenbach, 2012, Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients, Breast Cancer Res Treat, 134, 933, 10.1007/s10549-012-1988-6 · DOI

Cited by

Sorted by citations

Metadata

Authors
Jing, N., Yin, L., Sun, J., Cao, Z., & Mao, W.
Affiliations
  • Qingdao University, Qingdao, Shandong 266071, P.R. China
  • Department of Blood Purification, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China
  • Department of Anorectal Surgery, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China
  • Department of General Surgery, Qingdao Municipal Hospital, Qingdao, Shandong 266071, P.R. China
Venue
Oncology Letters
Publisher
Spandidos Publications
Published
2018-07-13
ISSN
  • 1792-1074
  • 1792-1082
DOI
10.3892/ol.2018.9146
PMC
PMC6126165
Cited by
0
References
0

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review